1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
3
|
Villar-Vázquez R, Padilla G,
Fernández-Aceñero MJ, Suárez A, Fuente E, Pastor C, Calero M,
Barderas R and Casal JI: Development of a novel multiplex
beads-based assay for autoantibody detection for colorectal cancer
diagnosis. Proteomics. 16:1280–1290. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
6
|
Pucci S, Bonanno E, Sesti F, Mazzarelli P,
Mauriello A, Ricci F, Zoccai GB, Rulli F, Galatà G and Spagnoli LG:
Clusterin in stool: A new biomarker for colon cancer screening? Am
J Gastroenterol. 104:2807–2815. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wang Y, Jiang X, Dong S, Shen J, Yu H,
Zhou J, Li J, Ma H, He E and Skog S: Serum TK1 is a more reliable
marker than CEA and AFP for cancer screening survey in a study of
56,286 people. Cancer Biomark. 16:529–536. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Hollis M, Nair K, Vyas A, Chaturvedi LS,
Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer:
Early detection, prognosis, and chemosensitivity. World J
Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Cortez MA, Bueso-Ramos C, Ferdin J,
Lopez-Berestein G, Sood AK and Calin GA: MicroRNAs in body
fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol.
8:467–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zeng JH, Liang L, He RQ, Tang RX, Cai XY,
Chen JQ, Luo DZ and Chen G: Comprehensive investigation of a novel
differentially expressed lncRNA expression profile signature to
assess the survival of patients with colorectal adenocarcinoma.
Oncotarget. 8:16811–16828. 2017.PubMed/NCBI
|
13
|
Sui J, Xu SY, Han J, Yang SR, Li CY, Yin
LH, Pu YP and Liang GY: Integrated analysis of competing endogenous
RNA network revealing lncRNAs as potential prognostic biomarkers in
human lung squamous cell carcinoma. Oncotarget. 8:65997–66018.
2017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Hari DM and Bilchik AJ: Clinical
decision-making and implementation challenges with the AJCC VII
staging system for colorectal carcinoma. J Surg Oncol. 105:221–222.
2011. View Article : Google Scholar
|
17
|
van Rossum LG, van Rijn AF, Laheij RJ, Van
Oijen MG, Fockens P, Van Krieken HH, Verbeek AL, Jansen JB and
Dekker E: Random comparison of guaiac and immunochemical fecal
occult blood tests for colorectal cancer in a screening population.
Gastroenterology. 135:82–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
18
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar
|
19
|
Kanaan Z, Rai SN, Eichenberger MR, Roberts
H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: A potential
diagnostic marker of colorectal cancer. Ann Surg. 256:544–551.
2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Spratlin JL, Hui D, Hanson J, Butts C and
Au HJ: Community compliance with carcinoembryonic antigen:
Follow-up of patients with colorectal cancer. Clin Colorectal
Cancer. 7:118–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ito M, Mitsuhashi K, Igarashi H, Nosho K,
Naito T, Yoshii S, Takahashi H, Fujita M, Sukawa Y, Yamamoto E, et
al: MicroRNA-31 expression in relation to BRAF mutation, CpG island
methylation and colorectal continuum in serrated lesions. Int J
Cancer. 135:2507–2515. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Colussi D, Brandi G, Bazzoli F and
Ricciardiello L: Molecular pathways involved in colorectal cancer:
Implications for disease behavior and prevention. Int J Mol Sci.
14:16365–16385. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Weng M, Wu D, Yang C, Peng H, Wang G, Wang
T and Li X: Noncoding RNAs in the development, diagnosis, and
prognosis of colorectal cancer. Transl Res. 181:108–120. 2017.
View Article : Google Scholar
|
24
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Pereira DM, Rodrigues PM, Borralho PM and
Rodrigues CM: Delivering the promise of miRNA cancer therapeutics.
Drug Discov Today. 18:282–289. 2013. View Article : Google Scholar
|
26
|
Bischoff A, Huck B, Keller B, Strotbek M,
Schmid S, Boerries M, Busch H, Müller D and Olayioye MA: miR149
functions as a tumor suppressor by controlling breast epithelial
cell migration and invasion. Cancer Res. 74:5256–5265. 2014.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhang G, Liu X, Li Y, Wang Y, Liang H, Li
K, Li L, Chen C, Sun W, Ren S, et al: EphB3-targeted regulation of
miR-149 in the migration and invasion of human colonic carcinoma
HCT116 and SW620 cells. Cancer Sci. 108:408–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Jeansonne D, DeLuca M, Marrero L, Lassak
A, Pacifici M, Wyczechowska D, Wilk A, Reiss K and Peruzzi F:
Anti-tumoral effects of miR-3189-3p in glioblastoma. J Biol Chem.
290:8067–8080. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Bian Y, Guo J, Qiao L and Sun X:
miR-3189-3p mimics enhance the effects of S100A4 siRNA on the
inhibition of proliferation and migration of gastric cancer cells
by targeting CFL2. Int J Mol Sci. 19:pii: E236. 2018. View Article : Google Scholar
|
30
|
Zhang J, Chong CC, Chen GG and Lai PB: A
Seven-microRNA expression signature predicts survival in
hepatocellular carcinoma. PLoS One. 10:e01286282015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Lu M, Kong X, Wang H, Huang G, Ye C and He
Z: A novel microRNAs expression signature for hepatocellular
carcinoma diagnosis and prognosis. Oncotarget. 8:8775–8784. 2017.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhang Y, Sui J, Shen X, Li C, Yao W, Hong
W, Peng H, Pu Y, Yin L and Liang G: Differential expression
profiles of microRNAs as potential biomarkers for the early
diagnosis of lung cancer. Oncol Rep. 37:3543–3553. 2017. View Article : Google Scholar : PubMed/NCBI
|
33
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kandimalla R, Gao F, Matsuyama T, Ishikawa
T, Uetake H, Takahashi N, Yamada Y, Becerra CR, Kopetz S, Wang X
and Goel A: Genome-wide discovery and identification of a novel
miRNA signature for recurrence prediction in stage II and III
colorectal cancer. Clin Cancer Res. Mar 7–2018.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|